← FDA DRUG APPROVALS

FDA ANDA · ANDA040778

OXYCODONE AND ACETAMINOPHEN

Sponsor: AMNEAL PHARMS NY

APPLICATION
ANDA040778
TYPE
ANDA
ORIGINAL APPROVAL
2007-11-27
LATEST ACTION
2026-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

OXYCODONE AND ACETAMINOPHENPrescription
ACETAMINOPHEN 325MG, OXYCODONE HYDROCHLORIDE 10MG · TABLET · ORAL
OXYCODONE AND ACETAMINOPHENPrescription
ACETAMINOPHEN 325MG, OXYCODONE HYDROCHLORIDE 7.5MG · TABLET · ORAL

Approval history

2026-06-18REMS · Supplement 35AP
2024-10-31REMS · Supplement 32AP
2024-03-13Labeling · Supplement 31 · standardAP
2024-01-03Labeling · Supplement 30 · standardAP
2024-01-03Labeling · Supplement 29 · standardAP
2024-01-03Labeling · Supplement 27 · standardAP
2021-03-04Labeling · Supplement 25 · standardAP
2019-10-07Labeling · Supplement 19 · standardAP
2018-09-21Labeling · Supplement 15 · standardAP
2018-09-18REMS · Supplement 16AP
2016-12-16Labeling · Supplement 14 · standardAP
2016-12-16Labeling · Supplement 13 · standardAP
2016-12-15Labeling · Supplement 11 · standardAP
2013-10-18Labeling · Supplement 9 · standardAP
2011-06-29Labeling · Supplement 6AP
2007-11-27OriginalREMSAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →